QIAGEN Completed FDA Study for QIAstat-Dx Meningitis/Enzephalitis Panel for Notfall Diagnosis

QIAstat-Dx Meningitis/Enzephalitis-Panel in the USA for the clinical clinical tests, a diagnosis of infections by nervous systems in our system // Fourth FDA approval in 2024 marked Meilenstein at the follow-up of special research for the USA developments QIAstat-Dx- Tests // QIAGEN offers an extensive portfolio of FDA-approved tests for infections of the Atemwege, des Gastrointestinal tracts and des Zentralen Nervensystems – weitere Erweiterungen planted // Thanks Echtzeit-PCR liefert QIAstat-Dx Ergebnisse in a single Stunde and gewährleistet so quick and pleasant experience regarding the investigation of clinical research

GERMANTOWN, Maryland and VENLO, Netherlands, November 04, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has determined that the U.S. Food and Drug Administration (FDA) has designated QIAstat-Dx Meningitis/Enzephalitis Panel for the clinical Einsatz Zugelassen hat.

It is the fourth syndromic test for QIAstat-Dx to achieve results in the US in 2024.

Meningitis (Entzündung der das Gehirn und das Rückenmark umgebenden Membran) and Enzephalitis (Entzündung im Gehirn) are Mediterranean nuts, which cause a gentle treatment. The damage caused by bacterial meningitis is caused by damage caused by Hörverlust, Hirnschäden und Krampfanfällen. It is an easy treatment to leave half of the patients and patients.¹

The Zahl of the cases of bacterial meningitis in the US has been on the market since 2014, but the fall is an impfquote of the Bundesstaat in the Bundesstaat.²

Much research in the US does not go beyond traditional microbiological tests, while the tests are often interpreted for 24 times, while the QIAstat-Dx Ergebnisse is in another fun situation. Traditional methods are very sensitive. These are separated, a patient or a patient can only contain a small amount of alcohol (liquid, the central nervous system) for tests.

“Ambulatory severe meningitis and enzephalitis can be diagnosed quickly. Gesundheitsdienstleister is also an evidentiary diagnosis, which in turn can help. The QIAstat-Dx Meningitis/Encephalitis Panel has addressed many revisions, with the disagreements and confronting the disagreements, said Fernando Beils, Senior Vice President and Leader of the Molecular Diagnosis Geschäftsbereichs at QIAGEN “This is four FDA tests for a QIAstat-Dx test in the year 2024 and a broadcast for our involvement, our tests in the US and around the world.”

The QIAstat-Dx Meningitis/Enzephalitis Panel is based on the fact that the QIAstat-Dx System likely has a problem with Echtzeit PCR Technology. The QIAstat-Dx-Panel analysis shows that more viral, bacterial and pill-like infections are caused by ambulatory meningitis/encephalitis.

The QIAstat-Dx system is as little as possible, because the Ergebnisse Schwellenwert-Zyklen (Cycle Threshold, kurz: Ct-Werte) and Amplifikationskurven are expanded. Thus, medical personal information can be collected on the latest clinical information, which is not available with endpunkt-PCR or other technologies.

This new panel is the four FDA tests of QIAstat-Dx panels in the year 2024 and follows the latest FDA tests for other tests:

• QIAstat-Dx Gastrointestinal panel 2
• QIAstat-Dx Respiratory Panel Plus
• QIAstat-Dx Respiratory Panel Mini

All QIAstat-Dx Panels are a cost-effective way to make the QIAstat-Dx ready. The cards see all the reactions, the soft drink is put in the anspruch for a minute and there are no more prizes to be won. The software interprets the signals from the response and is very good for your mistakes, both positive and negative. Try researching syndromic tests on the market for sale.

More information about QIAstat-Dx can be found at https://www.qiagen.com/products/diagnostics-and-clinical-research/infectious-disease/qiastat-dx-syndromic-testing/qiastat-dx-na

Uber QIAGEN
QIAGEN NV, a Dutch holding company, is a prosperous company engaged in extracting molecular molecular research from biological research. QIAGEN’s research technology ensures the processing and processing of DNA, RNA and proteins from Blut, Gewebe and other substances. Testing technology can perform this biomolecular analysis and analysis. Bioinformatics solutions and financial databases help interpret dating with more relevant and practically useful research. Automation integrations integrate these cost-effective testing workflows. QIAGEN makes more than 500,000 people available with the Bereichen Molekulare Diagnostik (Gesundheitsfürsorge) and Life Sciences (akademie Forschung, pharmakologische Fund und industrial Anwendungen, hauptsächlich Forensik) for Verfügung. Zum 30. June 2024 beschäftigte QIAGEN weltweit more than 5,900 employees in über 35 Standorten. More information about QIAGEN can be found at http://www.qiagen.com.

Forward-looking statement
Einige der Angaben in dieser Pressemitteilung im Sinne von Section 27A of the US Securities Act (US-Wertpapergesetz) von 1933 in ergänzter Fassung and Section 21E of the US Securities Exchange Act (US-Börsengesetz) von 1934 in ergänzter Fassung als zkunftsgerichttete Aussagen (‘forward ‘-looking statements”). Consider the notification of market-oriented products from QIAGEN, including the responses to the COVID-19 pandemic that produces products, the Zeitplan voor marktinführungen und Entwicklungen, regulische Genehmigungen, finanzielle und operative Prognosen, Wachstum , Expansion, Collaboration, Market, Strategy or operative enterprise were not limited to that of the erwartenden Ergebnisse voor de bereinigten Nettoumsatz und de bereinigten bewässerten Gewinn je Aktie, geschieht die op de Basis der Zeitiger Erwartungen en Annahmen, die met probabile auf dem Unsavory and risk-taking . This is the case: Risks in management and international management (einschließlich Auswirkungen von Währungsschwankungen und der Abhängigkeit von regulische sowie Logistikprozessen); Schwankungen der Betriebsergebnisse und je Verteilung auf unsere Kundengruppen; the market research for our products and knowledge in academic Research, Pharma, Testing and Molecular Diagnostics; Changes in our knowledge of our capabilities, our customers and our strategic partners, our knowledge and understanding of the environment, our technological progress, our knowledge of our quality and our QIAGEN products (einschließlich overall economics, quality and efficiency of our budgets and our budgets), that Möglichkeit, die regulatory products for our product, the quality of the products of QIAGEN, an integrated product and the regenlung-solcher products, the quality of the external products, new products to integrate, and the product of the law-bewerber to use who for the Wettbewerb zu schützen, Markttakzeptanz new products and integration requirements Geschäfte and technology; Maßnahmen von Regierungen; global or regional economic development; Wetter-oder transportbedingte Verzögerungen, Naturkatastrofen, Political Criticism or Criticism in the area of ​​​​Safety, a loss of Ausmaßes and the Dauer of the COVID-19 pandemic and – 3 – your Auswirkungen on the Nachfrage nach unseren Products and other Aspekte unseres s , or sonstige Ereignisse höherer Gewalt; so who has the power, as the erwartete Nutzen in the Zusammenhang with the young or anstehenden Acquisitionen, not who erwartet eintritt is; and other factors, see the “risk factors” in the annual report Form 20-F. More information can be found in messages sent by QIAGEN to the US Securities and Exchange Commission (US-Börsenaufsichtsbehörde).

Source: QIAGEN NV
Category: Business

Contact QIAGEN:

______________________________
1 https://www.who.int/news-room/fact-sheets/detail/meningitis, abgerufen am 30.10.2024
2 https://www.cdc.gov/meningococcal/php/surveillance/index.html, abgerufen on 30.10.2024

Quelle Hugin